Beryl Drugs Standalone March 2022 Net Sales at Rs 3.47 crore, down 42.8% Y-o-Y

Beryl Drugs Standalone June 2021 Net Sales At Rs 4.61 Crore, Up 70.95% Y-o-Y

Price return has been average, nothing exciting

Seems to be overvalued vs the market average

Financials growth has been moderate for a few years

Showing good signs of profitability & efficiency

Good time to consider, stock is not in the overbought zone

Beryl Drugs is engaged in the manufacturing of allopathic pharmaceuticals preparations.